CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 93 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q2 2020. The put-call ratio across all filers is 0.10 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,172,000 | +4085.7% | 9,892 | +4073.8% | 0.00% | – |
| Q4 2020 | $28,000 | -98.3% | 237 | -98.4% | 0.00% | -100.0% |
| Q3 2020 | $1,610,000 | +48.4% | 14,488 | +36.5% | 0.00% | 0.0% |
| Q2 2020 | $1,085,000 | +54150.0% | 10,617 | +46060.9% | 0.00% | – |
| Q1 2020 | $2,000 | -99.8% | 23 | -99.7% | 0.00% | -100.0% |
| Q4 2019 | $947,000 | -6.2% | 8,130 | -7.8% | 0.00% | 0.0% |
| Q3 2019 | $1,010,000 | +9.3% | 8,821 | -9.1% | 0.00% | 0.0% |
| Q2 2019 | $924,000 | +203.0% | 9,702 | +190.5% | 0.00% | – |
| Q1 2019 | $305,000 | -27.9% | 3,340 | -39.9% | 0.00% | – |
| Q4 2018 | $423,000 | +71.3% | 5,553 | +79.0% | 0.00% | – |
| Q3 2018 | $247,000 | +16.0% | 3,102 | +44.5% | 0.00% | – |
| Q2 2018 | $213,000 | -4.1% | 2,147 | -21.6% | 0.00% | – |
| Q1 2018 | $222,000 | +26.1% | 2,738 | +22.0% | 0.00% | – |
| Q4 2017 | $176,000 | -50.0% | 2,245 | -41.1% | 0.00% | – |
| Q3 2017 | $352,000 | – | 3,812 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Maso Capital Partners Ltd | 164,500 | $15,011,000 | 10.32% |
| HHLR ADVISORS, LTD. | 2,751,200 | $251,047,000 | 6.99% |
| Dalton Investments, Inc. | 113,851 | $10,389,000 | 4.54% |
| Point72 Hong Kong Ltd | 115,939 | $10,579,000 | 4.17% |
| York Capital Management Global Advisors, LLC | 991,233 | $90,450,000 | 4.05% |
| RUDMAN ERROL M | 58,000 | $5,293,000 | 3.57% |
| Greenwoods Asset Management Ltd | 479,580 | $43,762,000 | 2.69% |
| Parametrica Management Ltd | 3,663 | $334,000 | 0.71% |
| Temasek Holdings (Private) Ltd | 990,000 | $90,338,000 | 0.62% |
| Athos Capital Ltd | 8,290 | $756,000 | 0.49% |